Post-ischemic treatment of WIB801C, standardized Cordyceps extract, reduces cerebral ischemic injury via inhibition of inflammatory cell migration

Keyphrases

• Transient Middle Cerebral Artery Occlusion (tMCAO) 100%
• Cerebral Ischemic Stroke 100%
• Inflammatory Cell Infiltration 100%
• Infarct Volume 100%
• Ischemic Lesion 100%
• Cordyceps Extract 100%
• Macrophages 66%
• Reperfusion 66%
• Neurological Deficit 66%
• PMCAO 66%
• Anti-inflammatory Therapy 66%
• Antichemotactic Activity 66%
• Infiltration 33%
• Clinically Significant 33%
• Immunostaining 33%
• Orally Administered 33%
• Potential Therapeutics 33%
• Sprague-Dawley Rats 33%
• White Matter 33%
• Clinical Trials 33%
• Microglia 33%
• Inflammatory Diseases 33%
• Survival Rate 33%
• Chemotaxis 33%
• Immunomodulatory Activity 33%
• Ischemic Brain 33%
• Neuroprotection 33%
• Ischemia 33%
• Therapeutic Efficacy 33%
• Rat Microglia 33%
• Inflammatory Cells 33%
• Ischemic Stroke 33%
• Edema 33%
• Drug Candidates 33%
• Improved Survival 33%
• Cordyceps 33%
• Blood-brain Barrier 33%
• Long-term Survival Rate 33%
• Antiischemic Effect 33%
• Cordyceps Militaris 33%
• Ethnopharmacological Relevance 33%
• Cerebral Edema 33%
• Therapeutic Time Window 33%
• Blood-brain Barrier Disruption 33%
• Standardized Extract 33%
• Adenosine Receptor Agonists 33%
• Cordycepin 33%
• Cerebral Stroke 33%
• Positive Outcomes 33%
• Volume Deficit 33%
• White Matter Damage 33%
• Anti-ischaemic Drugs 33%
• Chinese Caterpillar Fungus 33%
• Neurobehavioral Deficits 33%
• Adenosine A3 Receptor 33%

Neuroscience

• Anti-Inflammatory 100%
• Microglia 100%
• Brain Ischemia 100%
• Macrophage 100%
• Cell Migration 100%
• Blood Brain Barrier 100%
• Receptor Agonists 50%
• Immunohistochemistry 50%
• Middle Cerebral Artery 50%
• Chemotaxis 50%
• Cerebral Edema 50%
• Adenosine Receptor 50%
• Adenosine A3 Receptor 50%
• Cordycepin 50%
• Ischemia 50%
• Cerebrovascular Accident 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Injury 100%
• Infarction 100%
• Cordyceps 100%
• Anti-Inflammatory Drug 66%
• Survival Rate 66%
• Brain Ischemia 66%
• Blood-Brain Barrier 66%
• Sprague Dawley Rat 33%
• Combination Therapy 33%
• Inflammatory Disease 33%
• Ischemia 33%
• Edema 33%
• Clinical Trial 33%
• Long Term Survival 33%
• Middle Cerebral Artery Occlusion 33%
• Cordycepin 33%
• Cerebrovascular Accident 33%
• Adenosine A3 Receptor 33%
• Brain Edema 33%
• Anti-Ischemic Drug 33%
• Adenosine Receptor Stimulating Agent 33%
• Ophiocordyceps Sinensis 33%